Key Highlights

  • Precision BioSciences (NASDAQ:DTIL) was quoted 17.49% higher near USD 9.54 on November 5, 2026, based on published market data, with trading Volume running at 5.79 times its typical level.
  • The company set the price of an underwritten offering worth about USD 125 million at USD 7.75 per share on November 5, 2026, with settlement anticipated on or about November 6, 2026.
  • The transaction includes 10,235,077 common shares along with pre-funded warrants covering up to 5,893,964 shares, with TD Cowen and Guggenheim Securities acting as lead bookrunners.
  • Proceeds will go toward PBGENE-HBV and PBGENE-DMD, the company's gene-editing programs for hepatitis B and Duchenne muscular dystrophy, along with general corporate needs.

The Offering Behind the Move

Precision BioSciences (NASDAQ:DTIL) disclosed on November 5, 2026 that it had priced an underwritten public offering of roughly USD 125 million before fees. Each common share went for USD 7.75 across 10,235,077 shares, while investors could take pre-funded warrants for up to 5,893,964 shares at USD 7.749995, which is the share price less a USD 0.000005 exercise price. Settlement is anticipated on or about November 6, 2026. TD Cowen and Guggenheim Securities served as joint book-running managers. Participants included First Light Asset Management, MPM BioImpact, Bleichroeder, Lynx1 Capital Management, Readout Capital, Aberdeen Investments and Driehaus Capital Management. The stock was quoted 17.49% higher near USD 9.54 on November 5, 2026, based on published market data, which sits above the offering price.

Mechanics of the Deal and Use of Funds

A pre-funded Warrant lets a buyer pay nearly the full price at the outset and exercise later for a token amount, which suits holders who want to remain under an ownership ceiling. Both instruments increase the share count, so current shareholders hold a thinner stake. Straight arithmetic on the disclosed terms yields about 16.1 million shares and USD 125 million, which comes to nearly half of the USD 266.51 million valuation shown by published market data, so dilution is significant. Proceeds will support PBGENE-HBV and PBGENE-DMD along with working capital. Published coverage reports a third-quarter 2026 net loss of about USD 7.6 million on November 3, 2026, and states that the hepatitis B candidate is moving toward a Phase 2 stage, with specifics to be found in the company filings.

Risks and Items to Monitor

Biotech stocks of this scale carry thin-liquidity and Reversal risk. A handful of trades can move the share price, spreads may be wide, and quoted moves can retrace, including after a large raise priced below the recent trading level. Clinical-stage gene editing brings trial, safety, Manufacturing and regulatory hazards, and findings from one study do not necessarily carry over to the next. Cash raised extends the runway but does not eliminate the need for more funding if development costs climb. With no positive earnings, value depends on pipeline progress rather than profit. Investors should monitor the offering closing, any further detail on the hepatitis B Phase 2 design and timing, and updates on the Duchenne program.

Where Things Stand

Precision BioSciences (NASDAQ:DTIL) is up 17.49% in the quoted session, most likely because a fully subscribed USD 125 million raise from specialist healthcare funds eases near-term funding concerns, even though it dilutes existing holders. The USD 7.75 offering price sits below the quoted USD 9.54 level, which illustrates how quickly sentiment can swing. The quoted gain is intraday and may reverse. Next up are the closing, development updates and the next quarterly report.